La Jolla Pharmaceutical Company (LJPC):企業の財務・戦略的SWOT分析

◆英語タイトル:La Jolla Pharmaceutical Company (LJPC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH66490FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

La Jolla Pharmaceutical Company (LJPC) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

La Jolla Pharmaceutical Company (La Jolla) discovers, develops and commercializes biopharmaceutical products for life threatening diseases. The company’s major product includes the US FDA approved Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its investigational product candidates include LJPC-0118 intended for the treatment of severe malaria and LJPC-401, a proprietary formulation of synthetic human hepcidin, an endogenous peptide hormone intended for the prevention of excessive iron accumulation in vital organs. The company sells Giapreza to hospitals in the US through a network of wholesale and specialty distributors. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company Key Recent Developments

Dec 31,2020: La Jolla Pharmaceutical announces financial results for the three and twelve months ended December 31, 2020
Nov 09,2020: La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2020
Oct 29,2020: La Jolla Pharmaceutical Company announces appointment of Larry Edwards
Sep 30,2020: La Jolla Pharmaceutical announces change of certain officers
Aug 06,2020: La Jolla Pharmaceutical announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
La Jolla Pharmaceutical Company – Key Facts
La Jolla Pharmaceutical Company – Key Employees
La Jolla Pharmaceutical Company – Key Employee Biographies
La Jolla Pharmaceutical Company – Major Products and Services
La Jolla Pharmaceutical Company – History
La Jolla Pharmaceutical Company – Company Statement
La Jolla Pharmaceutical Company – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
La Jolla Pharmaceutical Company – Business Description
La Jolla Pharmaceutical Company – SWOT Analysis
SWOT Analysis – Overview
La Jolla Pharmaceutical Company – Strengths
La Jolla Pharmaceutical Company – Weaknesses
La Jolla Pharmaceutical Company – Opportunities
La Jolla Pharmaceutical Company – Threats
La Jolla Pharmaceutical Company – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
La Jolla Pharmaceutical Company, Recent Deals Summary
Section 5 – Company’s Recent Developments
Dec 31, 2020: La Jolla Pharmaceutical announces financial results for the three and twelve months ended December 31, 2020
Nov 09, 2020: La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2020
Oct 29, 2020: La Jolla Pharmaceutical Company announces appointment of Larry Edwards
Sep 30, 2020: La Jolla Pharmaceutical announces change of certain officers
Aug 06, 2020: La Jolla Pharmaceutical announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate progress
Jul 28, 2020: Larry Edwards appointed president and chief executive officer of La Jolla Pharmaceutical Company
Jun 02, 2020: La Jolla Pharmaceutical Company announces board changes
May 04, 2020: La Jolla Pharmaceutical Company announces financial results for the three months ended March 31, 2020
Mar 02, 2020: La Jolla Pharmaceutical Company announces financial results for the three and twelve months ended December 31, 2019
Jan 09, 2020: La Jolla Pharmaceutical Company announces preliminary GIAPREZA (Angiotensin II) net sales for the three and twelve months ended December 31, 2019
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
La Jolla Pharmaceutical Company, Key Facts
La Jolla Pharmaceutical Company, Key Employees
La Jolla Pharmaceutical Company, Key Employee Biographies
La Jolla Pharmaceutical Company, Major Products and Services
La Jolla Pharmaceutical Company, History
La Jolla Pharmaceutical Company, Subsidiaries
La Jolla Pharmaceutical Company, Key Competitors
La Jolla Pharmaceutical Company, Ratios based on current share price
La Jolla Pharmaceutical Company, Annual Ratios
La Jolla Pharmaceutical Company, Annual Ratios (Cont...1)
La Jolla Pharmaceutical Company, Interim Ratios
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
La Jolla Pharmaceutical Company, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[La Jolla Pharmaceutical Company (LJPC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • San Raffaele Hospital-製薬・医療分野:企業M&A・提携分析
    Summary San Raffaele hospital (San Raffaele), a subsidiary of Vita-Salute San Raffaele University is a clinical scientific university institution that offers education and healthcare services. The institute provides services through the segments clinic, scientific research, patient services, and hos …
  • TH Heavy Engineering Berhad (THHEAVY):企業の財務・戦略的SWOT分析
    TH Heavy Engineering Berhad (THHEAVY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Inovio Pharmaceuticals Inc (INO)-医療機器分野:企業M&A・提携分析
    Summary Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing a portfolio of DNA vaccines (immunotherapies) for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology a …
  • PharmAust Ltd (PAA)-製薬・医療分野:企業M&A・提携分析
    Summary PharmAust Ltd (PharmAust) is a drug discovery and development company which provides human and veterinary proprietary medicines to treat different types of cancers. The company provides specialized medicinal and synthetic chemistry services. It specializes in bio defense and laboratory suppo …
  • Enzo Clinical Labs Inc-医療機器分野:企業M&A・提携分析
    Summary Enzo Clinical Labs Inc (Enzo Clinical), a subsidiary of Enzo Biochem Inc is a medical laboratory that offers testing services. The laboratory develops technologies in the areas of gene regulation and gene modification, biomedical and pharmaceutical research markets. It offers physicians seve …
  • Fresenius Kidney Care:医療機器:M&Aディール及び事業提携情報
    Summary Fresenius Kidney Care (FMCNA), formerly Fresenius Medical Care Holdings Inc, a subsidiary of Fresenius Medical Care AG & Co KGaA, is a provider of dialysis services and renal care products. The company’s dialysis products include hemodialysis; dialyzers, haemodialysis machines, FMiS medical …
  • AngioChem Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AngioChem Inc (AngioChem) is a clinical-stage biotechnology company that discovers and develops new drugs to treat brain related disorders. The company’s products comprise oncology products, peptide antibody conjugates, antibody-drug conjugates, pain products and lysosomal storage diseases p …
  • Viskase Companies Inc (VKSC):企業の財務・戦略的SWOT分析
    Viskase Companies Inc (VKSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Step Pharma SAS-製薬・医療分野:企業M&A・提携分析
    Summary Step Pharma SAS (Step Pharma) is a biotechnology company, which strives to discover and develop proprietary small molecule medicines for the treatment of auto-immune diseases. The company is developing a new class of oral nucleotide synthesis inhibitors against cytidine triphosphate synthase …
  • Zhejiang Yatai Pharmaceutical Co Ltd (002370):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Yatai Pharmaceutical Co Ltd (Yatai Pharmaceutical), formerly Asia-Pacific Pharmaceutical Factory, is a pharmaceutical company. The company develops, researches, and manufactures pharmaceuticals including penicillin, cephalosporins and hormones. It offers transdermal controlled-relea …
  • Time Inc.:企業のM&A・事業提携・投資動向
    Time Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Time Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Touchstone Group plc:企業の戦略的SWOT分析
    Touchstone Group plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • China Huaneng Group:発電所・企業SWOT分析
    China Huaneng Group - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Orpak Systems Limited:企業の戦略的SWOT分析
    Orpak Systems Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Crinetics Pharmaceuticals Inc (CRNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Crinetics Pharmaceuticals Inc (Crinetics) is a developer of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products include neuropeptides and their receptors, orally-available somatostatin agon …
  • Tarsa Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Tarsa Therapeutics Inc (Tarsa) develops therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the treatment of postmenopausa …
  • Tower International Inc (TOWR):企業の財務・戦略的SWOT分析
    Tower International Inc (TOWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • SomaLogic Inc:医療機器:M&Aディール及び事業提携情報
    Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products. The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the pr …
  • Partners Group Holding AG (PGHN):企業の財務・戦略的SWOT分析
    Summary Partners Group Holding AG (Partners Group) is a private market investment manager that offers private equity and investment services. The company manages investment programs and customized portfolios for institutional investors such as insurance companies, pension funds, and sovereign wealth …
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆